Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
41326340 (PubMed )
Supplement: 41392_2025_2481_MOESM1_ESM.docx
Mutational scanning reveals substrate-assisted autoregulation of the WNT destruction complex.
Padmanarayana M et al.
Biorxiv : the Preprint Server for Biology, 2025
41278994 (PubMed )
Supplement: media-1.xlsx › WNT_DC_CBE_Screen
Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer.
Wong AM et al.
Jhep Reports : Innovation in Hepatology, 2025
TP53 mutation status and consensus molecular subtypes of colorectal cancer in patients from Rwanda.
Nzitakera A et al.
Bmc Cancer, 2024
Next-Generation Sequencing Analysis of Mutations in Circulating Tumor DNA from the Plasma of Patients with Head-Neck Cancer Undergoing Chemo-Radiotherapy Using a Pan-Cancer Cell-Free Assay.
Koukourakis MI et al.
Current Oncology (toronto, Ont.), 2023
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
Miller AM et al.
Nature, 2019
30675060 (PubMed )
Supplement: NIHMS1516901-supplement-Sup_Table_5.xlsx › Matched_pair_analysis
Genetic characterisation of molecular targets in carcinoma of unknown primary.
Clynick B et al.
Journal of Translational Medicine, 2018
A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K et al.
Pathology, Research and Practice, 2015
Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
Kang HJ et al.
Plos One, 2013
Select a paper to view details